ASTRAZENECA PLC SPON ADR EACH REP 0.50 ORD SHSASTRAZENECA PLC SPON ADR EACH REP 0.50 ORD SHSASTRAZENECA PLC SPON ADR EACH REP 0.50 ORD SHS

ASTRAZENECA PLC SPON ADR EACH REP 0.50 ORD SHS

No trades
See on Supercharts

Key facts today


AstraZeneca's Imfinzi gained FDA approval as the first immunotherapy for muscle-invasive bladder cancer, showing a 32% lower recurrence risk and 25% lower death risk compared to chemotherapy.
AstraZeneca's Calquence has gained a positive nod from the European Medicines Agency for first-line treatment of untreated mantle cell lymphoma, showing a 27% lower risk of disease progression.
AstraZeneca's AZD0780 cut LDL cholesterol by 50.7% in a phase 2b trial. 84% of those on AZD0780 met LDL-C targets, with similar safety profiles to placebo.
Analyze the impactAnalyze the impact
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪229.03 B‬USD
‪7.04 B‬USD
‪54.07 B‬USD
‪3.10 B‬
Beta (1Y)
0.11

About ASTRAZENECA PLC ORD USD0.25


CEO
Pascal Soriot
Headquarters
Cambridge
Founded
1992
FIGI
BBG00X9DN9C1
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
US46353AX6
ASTRAZENECA 20/50
Yield to maturity
7.02%
Maturity date
Aug 6, 2050
US46353AZ1
ASTRAZENECA 21/51
Yield to maturity
6.39%
Maturity date
May 28, 2051
US46353AU2
ASTRAZENECA 18/48
Yield to maturity
5.85%
Maturity date
Aug 17, 2048
US46353AM0
ASTRAZENECA PLC 15/45
Yield to maturity
5.81%
Maturity date
Nov 16, 2045
AZN3901525
AstraZeneca PLC 4.0% 18-SEP-2042
Yield to maturity
5.74%
Maturity date
Sep 18, 2042
A
US4636NAN3
ASTRAZEN.FI. 24/34
Yield to maturity
4.96%
Maturity date
Feb 26, 2034
AZN.GE
AstraZeneca PLC 6.45% 15-SEP-2037
Yield to maturity
4.91%
Maturity date
Sep 15, 2037
A
AZN5193314
AstraZeneca Finance LLC 2.25% 28-MAY-2031
Yield to maturity
4.90%
Maturity date
May 28, 2031
US46353AW8
ASTRAZENECA 20/30
Yield to maturity
4.84%
Maturity date
Aug 6, 2030
A
AZN5549116
AstraZeneca Finance LLC 4.875% 03-MAR-2033
Yield to maturity
4.76%
Maturity date
Mar 3, 2033
50UC
ASTRAZENECA PLC 5.75% SNR EMTN 13/11/2031
Yield to maturity
4.69%
Maturity date
Nov 13, 2031

See all 0A4J bonds 


Check out other big names from the same industry as 0A4J.